首页>Journal of thrombosis and haemostasis: JTH>Phase I study of BAY 94-9027, a PEGylated B-domain-deleted recombinant factor VIII with an extended half-life, in subjects with hemophilia A
Phase I study of BAY 94-9027, a PEGylated B-domain-deleted recombinant factor VIII with an extended half-life, in subjects with hemophilia A
作者单位：Bayer HealthCare Pharmaceuticals, Whippany, NJ, United States[1]University of California, Davis, Sacramento, CA, United States[2]Upstate Medical University, State University of New York, Syracuse, NY, United States[3]University of Minnesota Medical Center, Minneapolis, MN, United States[4]Brigham and Women's Hospital, Boston, MA, United States[5]
换一批
